Last reviewed · How we verify
Tetanus and Diphtheria Toxoids Adsorbed
This vaccine stimulates the immune system to produce antibodies against tetanus and diphtheria toxins by presenting inactivated toxoids as antigens.
This vaccine stimulates the immune system to produce antibodies against tetanus and diphtheria toxins by presenting inactivated toxoids as antigens. Used for Prevention of tetanus, Prevention of diphtheria.
At a glance
| Generic name | Tetanus and Diphtheria Toxoids Adsorbed |
|---|---|
| Also known as | DECAVAC, Td, Tetanus and Diphtheria Toxoids Adsorbed for Adult Use |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Toxoid vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Tetanus and diphtheria toxoids are chemically inactivated bacterial toxins that cannot cause disease but retain immunogenicity. When administered, they trigger B and T cell responses that generate protective antibodies (antitoxins) against the respective toxins produced by Clostridium tetani and Corynebacterium diphtheriae. The adsorbed formulation enhances immunogenicity by binding toxoids to an aluminum salt adjuvant.
Approved indications
- Prevention of tetanus
- Prevention of diphtheria
Common side effects
- Injection site pain, erythema, or swelling
- Fever
- Myalgia
- Fatigue
Key clinical trials
- Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PHASE4)
- Immunosuppression and COVID-19 Boosters (PHASE3)
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine (PHASE1, PHASE2)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PHASE2)
- Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents (PHASE3)
- PFAS Exposure and Immune Response to Vaccination in Adults (PHASE4)
- Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |